Lilly merger strategy
Lilly is informally indicating its interest in the acquisition feelers for Searle. Lilly says it does not comment on specific merger candidates and professes confidence in its strategy of independent growth. The company says it is more interested in targeted collaborations on the model of the ReoPro agreement with Centocor. However, the company said it would consider acquisitions that enhance its innovation or improve its standing in selected international markets
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth